Siemens Healthineers showed examples at ACC 2022 of cardiac computed tomography (CT) from its new Naeotom Alpha photon-counting CT scanner cleared by the FDA in 2021.
Boston Scientific’s EMBOLD Fibered Detachable Coil.
It has been a busy few weeks for the FDA, with plenty of big-name approvals and recalls making the news, but there have also been some other big announcements related to solutions receiving FDA clearance.
Ami Bhatt, MD, the American College of Cardiology (ACC) chief innovation officer and adult congenital heart disease cardiologist at Mass General Hospital, discusses how to get physician acceptance to use artificial intelligence (AI).
The study's authors compared findings from the PROTECT-AF and PREVAIL clinical trials with data from the NCDR LAAO Registry, focusing on short-term and long-term outcomes.
Illustration showing four innovative heart failure technologies: The V-Wave interaterial shunt to relieve pressures between the left and right sides of the heart; the Carillon Transcatheter mitral valve annuloplasty system; the Revivent TC system and the AccuCinch device. Image courtesy of Cleveland Clinic.
The devices, currently being investigated by teams of heart specialists, could make a big impact in the years ahead.
Brugada arrhythmogenic substrate that causes VT and sudden cardiac death. This study showed ablation of this substrate area could help prevent sudden cardiac arrest in these patients.
A late-breaking study at Heart Rhythm 2022 found epicardial ablation in Brugada syndrome helped significantly reduce sudden cardiac arrest in these patients, increasing their survival.
A large proportion of patients with atrial fibrillation (AFib) end up in emergency rooms (ERs), but there are inherent issues with most hospital ERs handing off these patients to electrophysiologists for follow-up care.
Pulmonary vein isolation (PVI) using higher power energy ablation was found to be safe, more effective and was able to cut procedure time, but there was a signal of increased emboli.
New research, presented at Heart Rhythm 2022, found a 96% percent freedom from reoccurrence of atrial fibrillation in patients treated with high power vs. standard power radiofrequency ablation.
